The median PFS for patients with STK11 mutation and those with KEAP1 mutation were 6.1 and 5.1 months (Figures 2A, C), respectively, indicating that the clinical efficacy of ICIs combined with cytotoxic chemotherapy is also limited in NSCLC patients with both gene mutations. Here, KEAP1 is linked to non-small cell lung carcinoma.